The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

OBJECTIVE: Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster, and vaccination is recommended for patients ages 50 years and older, prior to starting treatment with biologic agents or tofacitinib. Tofacitinib is an oral JAK inhibitor for the treatment of RA. We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L., Wouters, Ann G., Choy, Ernest H., Soma, Koshika, Hodge, Jennifer A., Nduaka, Chudy I., Biswas, Pinaki, Needle, Elie, Passador, Sherry, Mojcik, Christopher F., Rigby, William F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656925/
https://www.ncbi.nlm.nih.gov/pubmed/28845577
http://dx.doi.org/10.1002/art.40187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656925/
https://www.ncbi.nlm.nih.gov/pubmed/28845577
http://dx.doi.org/10.1002/art.40187

Ejemplares similares